Jitai Pharmaceutical Debuts at DUPHAT 2026 Dubai, Expanding Strategic Footprint Across the MENA Pharma Market

Held at the Dubai International Convention & Exhibition Centre from August 25 to 27, 2026, the 31st Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT 2026) stands as the most authoritative and influential flagship pharmaceutical event across the Middle East and North Africa (MENA) region. Bringing together global API manufacturers, pharmaceutical distributors, regulatory experts and key procurement decision-makers, the exhibition serves as a premier cross-border platform for trade collaboration and technical exchange. It effectively connects upstream and downstream pharmaceutical resources with regional market demands, fosters in-depth cooperation across the industrial value chain, and advances the sustainable development of the entire MENA healthcare sector.

Yangling Jitai Pharmaceutical Co., Ltd. sent its dedicated international business team to participate in this influential industry gathering. Aligned with the core needs of the Middle Eastern pharmaceutical market, our team showcased the company’s robust API manufacturing expertise and comprehensive end-to-end service capabilities. Through face-to-face dialogues with global industry practitioners and local clients, Jitai gained actionable, on-the-ground insights into MENA market characteristics, procurement preferences and emerging trends. The participation further advances our global market expansion strategy and demonstrates the superior manufacturing reliability of Chinese API enterprises on the international stage.

As the longest-running and most prestigious pharmaceutical summit in the Middle East, DUPHAT 2026 centers on critical industry themes including API supply chain stability, international quality compliance, pharmaceutical technological innovation, sustainable production and streamlined regional market access. The event integrates high-quality industrial resources covering pharmaceutical R&D, pilot testing, commercial-scale production and global trade. Complementing onsite product exhibitions, a series of professional industry seminars addressed the latest local regulatory updates, supply chain resilience strategies, green manufacturing practices and shifting regional procurement priorities. These immersive industry exchanges enabled global peers to share practical operational experience, tackle common industry challenges and explore viable long-term cooperation opportunities. For Jitai Pharmaceutical, participation in DUPHAT 2026 delivered far beyond brand exposure. It offered direct, real-time market feedback, enabling us to precisely capture the unique product specifications, quality standards and service requirements of MENA pharmaceutical markets.

Headquartered in Shaanxi, China, Jitai Pharmaceutical is a specialized and trusted API manufacturer guided by technology-led quality improvement and sustainable development. Our 45,000-square-meter state-of-the-art production base features GMP-compliant full-scale workshops and an independent professional quality testing laboratory. We implement rigorous full-process quality control spanning raw material sourcing, production operation and finished product inspection, ensuring full compliance with international pharmaceutical standards and regulatory protocols. During the Dubai exhibition, our team presented our full spectrum of core API products, highlighting our mature production workflows, flexible custom order capabilities and complete regulatory documentation support. Our high-quality product portfolio and tailored industrial solutions garnered extensive attention and high recognition from buyers across the Middle East and global markets.

Over the three-day exhibition, Jitai’s international team conducted one-on-one business consultations and in-depth negotiations with global clients. Both parties exchanged detailed views on customized supply solutions, product quality specifications, optimized lead-time arrangements, regional registration support and comprehensive after-sales services. These targeted, professional discussions yielded fruitful outcomes, including multiple preliminary cooperation intentions and long-term partnership ties with high-quality prospective clients across the Middle East. Meanwhile, our team benchmarked against industry leaders onsite, learning about cutting-edge pharmaceutical manufacturing technologies, innovative industry developments and evolving market dynamics in the MENA region. These first-hand industry insights provide solid guidance for us to optimize our R&D roadmap, adjust product structures and refine localized market strategies.

Committed to empowering the advancement of global pharmaceutical healthcare, Jitai Pharmaceutical consistently delivers reliable, cost-effective and high-performance APIs, underpinned by stringent quality assurance systems, standardized production management and responsive customer-centric services. Our successful participation in DUPHAT 2026 marks a pivotal milestone in our strategic market expansion into the Middle East and North Africa region. Moving forward, we will continue to prioritize technological innovation and quality enhancement, optimize overseas supply systems and cross-border cooperation mechanisms, and pursue mutually beneficial global partnerships. We strive to grow alongside pharmaceutical enterprises across the MENA region and worldwide, contributing steady momentum to the healthy and sustainable development of the global pharmaceutical industry.